Evidence
What peptide studies actually show, which claims remain unproven, and how the regulatory record affects access. Each review gives a direct answer, the evidence behind it and the limits that matter when comparing treatments.
47 reviews · page 2 of 4
Does elamipretide improve fatigue and exercise capacity?
A 218-person trial in primary mitochondrial myopathy found no improvement in walking distance or fatigue; encouraging Barth syndrome extension results came from a different disease and an uncontrolled phase.
Does kisspeptin-10 treat low testosterone?
Small studies show hormone stimulation in healthy men, but they do not establish symptom improvement or treatment benefit in men with clinical hypogonadism.
Can setmelanotide trial results predict general weight loss?
No. The cited trials enrolled people with specific rare disorders, and their response rates cannot be applied to ordinary obesity or compared directly with unrelated weight-loss trials.
Does BPC-157 work when taken by mouth or as a nasal spray, and how do those forms compare with injection?
That is not known, because no published study has measured how much BPC-157 reaches the bloodstream when it is swallowed or sprayed into the nose, in people or in any animal, and none has compared either route with injection. The claim that it survives stomach acid comes from its originators' own reviews; the one oral trial in people, registered in 2015, has posted no results; and PubMed holds no study of nasal BPC-157 at all. The form does not change its legal position: as of September 2026 no pharmacy may lawfully compound it in any form.
What are the side effects of BPC-157, and what is actually known about its safety?
No controlled human study has measured the side effects of BPC-157, so no reliable list of them exists. Three uncontrolled reports from one clinic, covering 30 people, recorded no adverse events; FDA's stated concerns are immune reactions and impurities; and the cancer question is a theory drawn from animal biology, not an observation in people.
What is known about CJC-1295 taken with ipamorelin?
No study has tested the two together. CJC-1295's human record is two small hormone studies in healthy adults and a phase 2 trial stopped without results; ipamorelin's is a pharmacokinetic study and a postoperative trial that missed its endpoint; and neither molecule has a lawful compounding route in the United States.
What are the GLOW and KLOW peptide blends, and has either been tested in people?
Neither blend is an approved drug, and no human trial has tested either combination. Injectable GHK-Cu has no lawful compounding route, BPC-157, TB-500 and KPV await FDA action after an advisory vote, and none of the four has a published controlled trial as an injection.
Which incretin drugs are approved, which are still in trials, and which of them are peptides?
As of September 2026, five of the incretin drugs tracked here are FDA-approved: semaglutide, tirzepatide, liraglutide, dulaglutide and, since April 1, 2026, the orforglipron tablet sold as Foundayo. Retatrutide, CagriSema, zenagamtide (amycretin), survodutide and mazdutide remain investigational in the United States. All are peptides except orforglipron, a small molecule, and dulaglutide, a much larger fusion protein.
What is the difference between Melanotan I and Melanotan II?
Melanotan I is the research name of afamelanotide, which FDA approved in 2019 as Scenesse, an implant for adults with the rare light-sensitivity disease erythropoietic protoporphyria; Melanotan II is a different, non-selective compound with no approval, whose only tanning-related trial is a three-volunteer pilot from 1996 and whose later human record is mostly case reports of harm. No approved product is indicated for tanning, and material sold under either name is not Scenesse.
Which peptides sold for weight loss are actually FDA-approved for it?
Four, each for a specific label: semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Saxenda) for chronic weight management, and setmelanotide (Imcivree) only for rare genetic and hypothalamic obesity; tesamorelin is approved for a narrower use, AOD-9604 failed its human weight trial, and MOTS-c and retatrutide have no approved use at all.
How do Semax and Selank differ, and what is the evidence and legal status of each?
They share an origin and a gap. Both are short synthetic peptides developed in Russia, and every trial-type record for either one was published in Russian; Semax was studied in stroke and nerve disease, Selank in anxiety. Neither is approved or lawfully compoundable in the United States as of September 2026, though a federal advisory panel voted in July 2026 to recommend Semax for the compounding list and did not vote on Selank.
How do sermorelin and tesamorelin differ?
They share a mechanism and little else. Both are GHRH analogs that make the pituitary release its own growth hormone, but tesamorelin is the full 44-amino-acid hormone with an added hexenoyl group, licensed as a biologic for abdominal fat in HIV and barred from compounding, while sermorelin is the hormone's first 29 amino acids, a withdrawn approval with an old trial record that 503A pharmacies compound today.
A review argues from the ledger; the ledger itself is published as reference tables, and every molecule’s dated posture is in the molecule index. Terms of art are defined in the glossary.